DOCSLIB.ORG

Diagnosis and Management of Mitochondrial Disease: a Consensus Statement from the Mitochondrial Medicine Society

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diagnosis and Management of Mitochondrial Disease: a Consensus Statement from the Mitochondrial Medicine Society Systematic Review © American College of Medical Genetics and Genomics © American College of Medical Genetics and Genomics SYSTEMATIC REVIEW Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society Sumit Parikh, MD1, Amy Goldstein, MD2, Mary Kay Koenig, MD3, Fernando Scaglia, MD4, Gregory M. Enns, MD5, Russell Saneto, MD, PhD6,7, Irina Anselm, MD8, Bruce H. Cohen, MD9, Marni J. Falk, MD10, Carol Greene, MD11, Andrea L. Gropman, MD12, Richard Haas, MB BChir, MRCP13, Michio Hirano, MD14, Phil Morgan, MD15, Katherine Sims, MD16, Mark Tarnopolsky, MD, PhD17, Johan L.K. Van Hove, MD18, Lynne Wolfe, MS, CRNP19 and Salvatore DiMauro, MD20 Purpose: Te purpose of this statement is to review the literature Results: Consensus-based recommendations are provided for the regarding mitochondrial disease and to provide recommendations diagnosis and treatment of mitochondrial disease. for optimal diagnosis and treatment. Tis statement is intended for Conclusion: Te Delphi process enabled the formation of physicians who are engaged in diagnosing and treating these patients. consensus-based recommendations. We hope that these recom- Methods: Te Writing Group members were appointed by the mendations will help standardize the evaluation, diagnosis, and care Mitochondrial Medicine Society. Te panel included members with of patients with suspected or demonstrated mitochondrial disease. expertise in several diferent areas. Te panel members utilized a comprehensive review of the literature, surveys, and the Delphi Genet Med advance online publication 11 December 2014 method to reach consensus. We anticipate that this statement will Key Words: consensus criteria; Delphi method; mitochondrial need to be updated as the feld continues to evolve. disease; mitochondrial medicine; Mitochondrial Medicine Society Mitochondrial diseases are one of the most common inborn Tere are no published consensus-based practice parameters errors of metabolism, with a conservative estimated prevalence that clinicians can utilize for initiating diagnosis or patient of approximately 1:5,000. Primary mitochondrial diseases are management. Most mitochondrial medicine specialists use a defned as disorders impacting the structure or function of the set of internally established guidelines based on theoretical con- mitochondria as a result of either nuclear DNA (nDNA) or cepts, limited published recommendations, and personal and 1 Genet Med mitochondrial DNA (mtDNA) mutations. anecdotal experience. As the Mitochondrial Medicine Society Te feld of mitochondrial medicine has only developed over recently assessed, notable variability exists in the diagnostic the past 25 years, and clinicians have limited but growing evi- approaches used, extent of testing sent, interpretation of test 2014 dence to formulate clinical decisions regarding diagnosis, treat- results, and evidence from which a diagnosis of mitochondrial ment, and day-to-day patient management. Tese disorders still disease is derived.2 Tere are also inconsistencies in treatment 00 lack sufciently sensitive and specifc biomarkers. Most current and preventive care regimens. diagnostic criteria were developed prior to the recent expansion Our purpose here was to review the literature on mito- 00 in genetic knowledge that allows precise delineation of specifc chondrial disease and, whenever possible, make consensus- disease etiologies. Establishing a diagnosis ofen remains chal- based recommendations for the diagnosis and management 18July2014 lenging, costly, and, at times, invasive. of these patients. In the interest of brevity, limited background 6November2014 1Department of Neurology, Center for Child Neurology, Cleveland Clinic Children’s Hospital, Cleveland, Ohio, USA; 2Department of Pediatrics, Division of Child Neurology, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA; 3Department of Pediatrics, Division of Child and Adolescent Neurology, University of Texas Medical School at 10.1038/gim.2014.177 Houston, Houston, Texas, USA; 4Department of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas, USA; 5Department of Pediatrics, Division of Medical Genetics, Stanford University Lucile Packard Children’s Hospital, Palo Alto, California, USA; 6Department of Neurology, Seattle Children’s Hospital, University of Washington, Seattle, Washington, USA; 7Department of Pediatrics, Seattle Children’s Hospital, University of Washington, Seattle, Washington, USA; 8Department of Genetics in Medicine Neurology, Boston Children’s Hospital, Boston, Massachusetts, USA; 9Department of Pediatrics, NeuroDevelopmental Science Center, Children’s Hospital Medical Center of Akron, Akron, Ohio, USA; 10Division of Human Genetics, Department of Pediatrics, The Children’s Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA; 11Department of Pediatrics, University of Maryland Medical Center, Baltimore, Maryland, USA; 12Department of Neurology, Children’s National 00 Medical Center and the George Washington University of the Health Sciences, Washington, DC, USA; 13Department of Neurosciences and Pediatrics, UCSD Medical Center and Rady Children’s Hospital San Diego, La Jolla, California, USA; 14Department of Neurology, Columbia University Medical Center, New York, New York, USA; 15Department of Anesthesiology, Seattle Children’s Hospital, Seattle, Washington, USA; 16Department of Neurology, Harvard Medical School and Massachusetts General Hospital, Boston, 00 Massachusetts, USA; 17Department of Pediatrics and Medicine, McMaster University, Hamilton, Ontario, Canada; 18Department of Pediatrics, Clinical Genetics and Metabolism, Children’s Hospital Colorado, Denver, Colorado, USA; 19National Institutes of Health, Bethesda, Maryland, USA; 20Department of Neurology, Columbia University Medical Center, New York, New York, USA. Correspondence: Sumit Parikh ([email protected]) Submitted 18 July 2014; accepted 6 November 2014; advance online publication 11 December 2014. doi:10.1038/gim.2014.177 11December2014 GENETICS in MEDICINE 1 SYSTEMATIC REVIEW PARIKH et al | Mitochondrial disease consensus criteria information about mitochondrial diseases, including testing, completion of a second set of surveys, a meeting of the panel diagnostics, and treatment approaches is provided. We direct was convened in conjunction with the 2014 annual meeting of the reader who may be unfamiliar with these topics to several the United Mitochondrial Disease Foundation Symposium in excellent reviews3–6 and to the supplementary material accom- Pittsburgh, Pennsylvania, where items that did not reach con- panying this review for comprehensive topic-specifc summa- sensus were discussed. Consensus was not reached for all items ries prepared as part of this consensus development endeavor. during the face-to-face meeting, especially on items that were considered to need further research. METHODS To maintain brevity, the full data summary for each topic Writing Group members were appointed by the Mitochondrial reviewed is not outlined below. All data summaries used by Medicine Society’s Consensus Criteria Committee. Te panel the working groups along with the initial composite consensus included 19 mitochondrial medicine specialists through- scores are available for review as an online supplement at out North America with diferent areas of expertise, includ- bit.ly/mmsdatasummaries and provide a comprehensive and ing neurologists, geneticists, clinical biochemical geneticists, in-depth review of these topics. anesthesiologists, and academic diagnostic laboratory direc- tors. Clinician-led subgroups were formed to review relevant DIAGNOSIS literature via a detailed PubMed search and summarize the Biochemical testing in blood, urine, and spinal fluid evidence on selected topics in mitochondrial disease. Because Most diagnostic algorithms recommend evaluation of selected some aspects of mitochondrial disease have been studied more mitochondrial biomarkers in blood, urine, and spinal fuid. thoroughly, these topics received more attention than others. Tese typically include measurements of lactate and pyruvate in We expected that there would be variable but generally limited plasma and cerebrospinal fuid (CSF), plasma, urine, and CSF data available to establish evidence-based clinical practice pro- amino acids, plasma acylcarnitines, and urine organic acids. tocols. Case reports and a limited number of case series are the Lactate elevation occurs because the fux through glycolysis primary evidence base available for the diagnosis and treatment overwhelms the utilization of pyruvate in the mitochondria. of mitochondrial disease. Few studies were prospective. An ini- Its usefulness is ofen limited by errors in sample collection tial approach to categorize the literature based on the Oxford and handling.3 Venous plasma lactate levels can be spuriously Centre for Evidence-Based Medicine system showed that the elevated if a tourniquet is applied during the collection and/or majority of the literature met grade 3 or less (case–control, low- if a child is struggling during the sampling. Markedly elevated quality cohort studies, or expert opinion without explicit critical plasma lactate (>3 mmol/l), in a properly collected sample, sug- appraisal). Tus, the panel was asked to develop consensus rec- gests the presence of mitochondrial dysfunction, which can be ommendations using the Delphi method. Delphi is a consensus
Load more

Recommended publications
  • Leigh Disease Associated with a Novel Mitochondrial DNA ND5 Mutation
    European Journal of Human Genetics (2002) 10, 141 ± 144 ã 2002 Nature Publishing Group All rights reserved 1018-4813/02 $25.00 www.nature.com/ejhg SHORT REPORT Leigh disease associated with a novel mitochondrial DNA ND5 mutation Robert W Taylor*,1, Andrew AM Morris2, Michael Hutchinson3 and Douglass M Turnbull1 1Department of Neurology, The Medical School, University of Newcastle upon Tyne, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK; 2Department of Metabolic Medicine, Great Ormond Street Hospital, London, WC1N 3JH, UK; 3Department of Neurology, St Vincent's University Hospital, Dublin, Republic of Ireland Leigh disease is a genetically heterogeneous, neurodegenerative disorder of childhood that is caused by defects of either the nuclear or mitochondrial genome. Here, we report the molecular genetic findings in a patient with neuropathological hallmarks of Leigh disease and complex I deficiency. Direct sequencing of the seven mitochondrial DNA (mtDNA)-encoded complex I (ND) genes revealed a novel missense mutation (T12706C) in the mitochondrial ND5 gene. The mutation is predicted to change an invariant amino acid in a highly conserved transmembrane helix of the mature polypeptide and was heteroplasmic in both skeletal muscle and cultured skin fibroblasts. The association of the T12706C ND5 mutation with a specific biochemical defect involving complex I is highly suggestive of a pathogenic role for this mutation. European Journal of Human Genetics (2002) 10, 141 ± 144. DOI: 10.1038/sj/ejhg/5200773 Keywords: Leigh disease; complex I; mitochondrial DNA; mutation; heteroplasmy Introduction mutations in the tRNALeu(UUR) gene,3 and a G14459A Leigh disease is a neurodegenerative condition with a variable transition in the ND6 gene that has previously been clinical course, though it usually presents during early characterised in patients with Lebers hereditary optic childhood.
    [Show full text]
  • Of the Workshops “Current Trends in Biomedicine” (Baeza, Spain; 2004-2019; Editions: 16 / Workshops: 64)
    INDEX OF TITLES AND ORGANIZERS (CHRONOLOGICAL ORDER) OF THE WORKSHOPS “CURRENT TRENDS IN BIOMEDICINE” (BAEZA, SPAIN; 2004-2019; EDITIONS: 16 / WORKSHOPS: 64) 2004: - “ORIGIN AND EVOLUTION OF HUMAN PATHOGENS” 20-23 OCTOBER 2004 Organizers: Josep Casadesús (Universidad de Sevilla. Sevilla, Spain) Eduardo A. Groisman (Washington University. St. Louis, USA) - “COUPLING BETWEEN TRANSCRIPTION AND RNA PROCESSING” 8-10 NOVEMBER 2004 Organizers: Miguel Beato (Centre de Regulació Genòmica (CRG). Barcelona, Spain) Frank Gannon (European Molecular Biology Laboratory (EMBL). Heidelberg, Germany) Juan Valcárcel (Centre de Regulació Genòmica (CRG). Barcelona, Spain) Editions 2005-2008 were organized jointly with the “Instituto de Salud Carlos III”: 2005: - “IMAGING SYNAPSES: FROM INDIVIDUAL MOLECULES TO BRAIN CIRCUITS” 2-5 OCTOBER 2005 Organizers: Rafael Fernández-Chacón (Universidad de Sevilla. Sevilla, Spain) Arthur Konnerth (Technical University Munich. Munich, Germany) Thomas C. Südhof (UT Southwestern Medical Center. Dallas, USA) - “CARDIOVASCULAR DEVELOPMENT: TOWARDS BIOMEDICAL APPLICABILITY” 23-26 OCTOBER 2005 Organizers: Marina Campione (University of Padua. Padua, Italy) Diego Franco (Universidad de Jaén. Jaén, Spain) Robert Kelly (University of Marseille. Marseille, France) - “EPIGENETIC MECHANISMS IN DEVELOPMENT AND DISEASE” 13-16 NOVEMBER 2005 Organizers: Adrian Bird (University of Edinburgh. Edinburgh, UK) José C. Reyes (Instituto de Bioquímica Vegetal y Fotosíntesis de Sevilla. Sevilla, Spain) Moshe Yaniv (Institute Pasteur. Paris, France) - “SYNAPTOPATHIES AND MENTAL DISORDERS” 11-14 DICIEMBRE 2005 Organizers: Guillermo Álvarez de Toledo (Universidad de Sevilla. Sevilla, Spain) Reinhard Jahn (Max Planck Institute for Biophysical Chemistry. Göttingen, Germany) 2006: - “RNA IN DISEASE AND THERAPY” 2-4 OCTOBER 2006 Organizers: Alfredo Berzal-Herranz (Instituto de Parasitología y Biomedicina "López-Neyra", CSIC. Granada, Spain) Bryan R.
    [Show full text]
  • Consensus-Based Statements for the Management of Mitochondrial Stroke-Like Episodes[Version 1; Peer Review: 2 Approved]
    Wellcome Open Research 2019, 4:201 Last updated: 02 OCT 2020 RESEARCH ARTICLE Consensus-based statements for the management of mitochondrial stroke-like episodes [version 1; peer review: 2 approved] Yi Shiau Ng 1-3, Laurence A. Bindoff4,5, Gráinne S. Gorman1-3, Rita Horvath1,6, Thomas Klopstock7-9, Michelangelo Mancuso 10, Mika H. Martikainen 11, Robert Mcfarland 1,3,12, Victoria Nesbitt13,14, Robert D. S. Pitceathly 15,16, Andrew M. Schaefer1-3, Doug M. Turnbull1-3 1Wellcome Centre for Mitochondrial Research, Newcastle University, UK, Newcastle upon Tyne, Tyne and Wear, NE2 4HH, UK 2Directorate of Neurosciences, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, Tyne and Wear, NE1 4LP, UK 3NHS Highly Specialised Service for Rare Mitohcondrial Disorders, Royal Victoria Infirmary, Newcastle upon Tyne, UK 4Department of Clinical Medicine, University of Bergen, Bergen, Norway 5Department of Neurology, Haukeland University Hospital, Bergen, Norway 6Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK 7Department of Neurology, Friedrich-Baur-Institute, University Hospital of the Ludwig-Maximilians-Universität München, Munich, Germany 8German Center for Neurodegenerative Diseases (DZNE), Munich, Germany 9Munich Cluster for Systems Neurology (SyNergy), Munich, Germany 10Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy 11Division of Clinical Neurosciences, University of Turku and Turku University Hospital, Turku, Finland 12Great North Children Hospital, Newcastle
    [Show full text]
  • Understanding and Coping with Mitochondrial Disease
    From the parents’ view … When we first heard that our daughter, Alexis, was diagnosed with Mitochondrial disease, we really didn't know what it was. We also learned that not too many people had heard of it before. Our daughter had many tests performed to reach the diagnosis of Mitochondrial disease. So once we received the news we were actually glad to finally have some answers. No parent wants their child to be ill, but we have learned to accept the disease and live with it on a day to day basis. We also learned that each person with Mitochondrial disease is affected differently by it. Alexis is severely affected by the disease, so each day with her is special. Meeting other children with Mitochondrial disease and their families have become a great support for us. We can relate to their daily struggles and if we need advice, they are there for us. My advice that I would give to others affected by Mitochondrial disease is to not give up. We can all fight this disease together. The hardest part sometimes is people not knowing enough about the disease. We really need to start educating people about it. Chris and Stephanie Understanding and coping with Mitochondrial disease A guide for parents The health care team at the Neuromuscular and Neurometabolic Centre wrote this book to answer some common questions about Mitochondrial disease. We hope that you will find it helpful. During your child’s care, you will meet the members of our team. We will work closely with you and your child to meet your needs.
    [Show full text]
  • How Do We Manage Stroke-Like Episodes?
    Mitochondrial diseases in adults: how do we manage stroke-like episodes? Dr Robert Pitceathly Senior Clinical Research Associate MRC Centre for Neuromuscular Diseases UCL, London Overview • Mitochondria and mitochondrial disease • What are stroke-like episodes? • Recognition of stroke-like episodes • Management of stroke-like episodes Mitochondria and mitochondrial disease The mitochondrion mtDNA and mitochondrial diseases 0 16,569 >250 pathogenic mutations Genetics of mitochondrial disease 37 genes > 1000 genes Genes of mitochondria-localised proteins linked to human disease Koopman WJ et al. N Engl J Med 2012;366:1132-1141 Genetic variability nDNA mtDNA 13 polypeptide subunits 7/44 0/4 1/11 3/14 2/16 Clinical variability Respiratory Failure Optic Atrophy / Retinitis Pigmentosa / Cataracts Cardiomyopathy / Conduction Defects CVA / Seizures / Developmental Delay Liver / Renal Failure Deafness Short stature / Marrow Failure Peripheral Diabetes Neuropathy Hypothyroidism Myopathy Clinical variability Age of onset Neonate Infant Child Adolescent Adult Elderly Congenital Lactic LS Acidosis PMPS HCM Alpers KSS MELAS CPEO MERRF NARP Exercise intolerance Myopathy How common is Mitochondrial Disease? Minimum point prevalence (mtDNA mutations): 1, in 5,000 Overt disease due to nDNA mutations: 2.9 per 100,000 Prevalence (total): 1 in 4,300 Mutation Affected ‘At Risk’ per 100,000 (CI) LHON 3.7 (2.9-4.6) 4.4 (3.7-5.3) m.3243A>G 3.5 (2.7-4.4) 4.4 (3.7-5.3) mtDNA 1.5 (1.0-2.1) 0 deletion m.8344A>G 0.2 (0.1-0.5) 0.5 (0.2-0.8) SPG7, ar 0.8 (0.5-1.3) 1.3
    [Show full text]
  • Migraines: Genetic Studies Pietro Cortelli Mirella Mochi and Some Practical Considerations
    J Headache Pain (2003) 4:47–56 DOI 10.1007/s10194-003-0030-0 EDITORIAL Pasquale Montagna The “typical” migraines: genetic studies Pietro Cortelli Mirella Mochi and some practical considerations Abstract Epidemiological genetic, in the inflammation cascade; etc.) family and twin studies show that the did not result in uniformely accepted typical migraines carry a substantial findings. Linkage and genome wide genetic risk; they are currently con- scans gave evidence for several ceptualized as complex genetic dis- genetic susceptibility loci, still how- ౧ P. Montagna ( ) • M. Mochi eases. Several genetic association ever in need of confirmation. Careful Department of Clinical Neurosciences, University of Bologna Medical School, and linkage studies have been per- dissection of the clinical phenotypes Via Ugo Foscolo 7, I-40123 Bologna, Italy formed in the typical migraines. and trigger factors shall greatly help e-mail: [email protected] Candidate gene studies based on “a future efforts in the quest for the Tel.: +39-051-6442179 priori” pathogenic models of genetic basis of the typical Fax: +39-051-6442165 migraine (migraine as a calcium migraines. P. Cortelli channelopathy; a mitochondrial Department of Neurology, DNA disorder; a disorder in the University of Modena and Reggio Emilia, metabolism of serotonin or Key words Migraine • Aura • Modena, Italy dopamine; in vascular risk factors or Genetics • Cardiovascular risk prove heritability, since it may result from shared envi- “Typical” migraine as a complex disease: genetic ronmental factors. It is therefore interesting to note that at epidemiology, twin and segregation analysis studies least one genetic epidemiology survey found an increased disease risk for migraine in first-degree relatives com- That migraine runs in families is an ancient observation.
    [Show full text]
  • What Are Mitochondria and Mitochondrial Disease? What Does It Mean for Dysautonomia?
    The Basics: What Are Mitochondria and Mitochondrial Disease? What Does It Mean For Dysautonomia? Richard G. Boles, M.D. Medical Director, Courtagen Life Sciences, Inc. Woburn, Massachusetts Medical Geneticist in Private Practice Pasadena, California Dysautonomia International; 18-July, 2015 Herndon, Virginia Disclosure: Dr. Boles wears many hats Dr. Boles is a consultant for Courtagen, which provides diagnostic testing. • Medical Director of Courtagen Life Sciences Inc. – Test development – Test interpretation – Marketing • Researcher with prior NIH and foundation funding – Studying sequence variation that predispose towards functional disease – Treatment protocols • Clinician treating patients – Interest in functional disease (CVS, autism) (((((((((((( ! Ri chard G. Boles, M.D. – Geneticist/pediatrician 20 years at CHLA/USC! Medical Genetics ! Pasadena, California – In private practice since 2014 ! ( ! ( Richard(G.(Boles,(MD( 1( ( July(16,(2014(( Disclosure: Off-label Indications There are no approved treatments for mitochondrial disease. Everything is “off label” Payton, 15-year-old • Presented to my clinic at age 11 years. • Cyclic vomiting syndrome from ages 1-10 years, with 2-day episodes twice a month of nausea, vomiting and lethargy. • Episodes had morphed into daily migraine. • Chronic pain throughout her body. • Chronic fatigue syndrome = chief complaint. • Substantial bowel dysmotility/IBS Multiple admissions for bowel clean-outs. • Excellent student • Pedigree: probable maternal inheritance 4 TRAP1-Related Disease (T1ReD) Mitochondrion, 2015 • NextGen sequencing at age 14 years revealed the p.Ile253Val variant in the TRAP1 gene. • TRAP1 encodes a mitochondrial chaperone involved in antioxidant defense. • This patient is one of 26 unrelated cases identified by Courtagen to date who have previously unidentified disease associated with mutations in the ATPase domain.
    [Show full text]
  • Predisposition to Infection and SIRS in Primary Mitochondrial Disorders: 8 Years’ Experience in an Academic Center
    Predisposition to infection and SIRS in primary mitochondrial disorders: 8 years’ experience in an academic center Target Audience: patients and families affected by primary mitochondrial disorders, primary care providers Melissa A. Walker MD, PhD, Katherine B. Sims MD, Jolan E. Walter MD, PhD Massachusetts General Hospital, Boston, MA Infection and Immune Function in Primary Mitochondrial Disorders • Introduction • Primary mitochondrial disorders • The immune system • Review of MGH mitochondrial patient registry (8 years’ experience) • Patients & diagnoses • Experience with • Infections • System immune response syndrome (SIRS) • Immunodysfunction • Clinical implications & future directions Primary Mitochondrial Disorders • Cause: dysfunction of the mitochondrion, the “powerhouse” organelle of the cell • Mitochondrial functions • Oxidative-phosphorylation (energy production) • Fatty acid oxidation (energy metabolism) • Apoptosis (controlled cell death) • Calcium regulation • Epidemiology • Estimated ~1:4000 individuals affected Diagnosis of Primary Mitochondrial Disorders Goal: determine the probability and possible cause of primary mitochondrial disease • Problems: • No single way to diagnose • Can affect multiple organ systems • No definitive biomarker (blood test) • Not all genes known • Phenotypic variation (same gene, different symptoms) • Heteroplasmy (unequal distribution of mitochondria & their DNA in cells) & maternal inheritance • Secondary mitochondrial dysfunction can mimic primary mitochondrial disorders Diagnosis of Primary
    [Show full text]
  • Mitochondrial Medicine 2019: Washington DC Scientific and Clinical Meetings June 26-29, 2019 Hilton Alexandria Mark Center Alexandria, VA
    Mitochondrial Medicine 2019: Washington DC Scientific and Clinical Meetings June 26-29, 2019 Hilton Alexandria Mark Center Alexandria, VA 2019 Course Chairs: Amel Kara, MD and Carla Koehler, PhD 2019 CME Chair: Bruce H. Cohen, MD Mitochondrial Medicine 2019: Washington DC Scientific/Clinical Program June 26-29, 2019 Course Description The United Mitochondrial Disease Foundation and PeerPoint Medical Education Institute have joined efforts to sponsor and organize a CME-accredited symposium. Mitochondrial diseases are more common than previously recognized and mitochondrial pathophysiology is now a recognized part of many disease processes, including heart disease, cancer, AIDS and diabetes. There have been significant advances in the molecular genetics, proteomics, epidemiology and clinical aspects of mitochondrial pathophysiology. This conference is directed toward the scientist and clinician interested in all aspects of mitochondrial science. The content of this educational program was determined by rigorous assessment of educational needs and includes surveys, program feedback, expert faculty assessment, literature review, medical practice, chart review and new medical knowledge. The format will include didactic lectures from invited experts intermixed with peer-reviewed platform presentations. There will be ample time for professional discussion both in and out of the meeting room, and peer-reviewed poster presentations will be given throughout the meeting. This will be a four-day scientific meeting aimed at those with scientific and
    [Show full text]
  • Summary – Pain Dr. Irina Anselm
    Summary – Pain Dr. Irina Anselm Pain is a very common feature of any chronic disease and patients with mitochondrial disease frequently suffer from different types of pain. Almost any organ or system may be involved in patients with Mito, and thus they may have a variety of pains. Pediatric pain in particular is a very difficult area, as it is very hard for physicians to watch children suffering. Up until a few years ago there was not much information on how to approach and assess pain in children who are very young or those who are nonverbal. However, research now indicates that the best gauge of pain in both children and adults is patient (or parent) report, and that children should be treated for suspected pain. What types of pain or pain syndromes are most frequently seen in children and in adults with Mito? I. Headaches are very common. Patients may suffer from migraines, tension headaches, chronic daily headaches and combinations of these. Are mechanisms of these headaches different from those in patients who don't have mitochondrial disorders? No one can answer this question with 100% certainty. My approach to the treatment of headaches in individuals with mitochondrial disease is not that much different from our approach to headache in other patients with several exceptions: • Treatment is based on frequency and severity of the headaches. For example, if they occur once or even twice a month, it is probably not worth treating the patient with prophylactic medicine. Prophylactic or preventive approach means that the patient takes medication every day.
    [Show full text]
  • MITOCHONDRIAL News
    UNITED MITOCHONDRIAL DISEASE FOUNDATION MITOCHONDRIAL NEWS TWO UMDF FUNDED RESEARCH smoking engine), Enns found that patients with a CONTENTS mitochondrial disorder had their natural antioxidant GRANTS RESULT IN NEW defense system overtaxed by the free radicals. INFORMATION “Even when these patients are coming into the Ask The Mito DocSM clinic looking pretty healthy, they have evidence of 3 One of the main mission points for the United extra metabolic stress,” Enns said, noting the findings Mitochondrial Disease Foundation is research. Since were surprising because none of the patients were Chapter Activities 1996, the UMDF has funded more than $6 Million in in the midst of a health crisis, such as organ failure, 4 research projects aimed at finding better treatments, when blood samples were drawn. diagnosis and ultimately a cure for mitochondrial “It is the first time such signs have been Fundraising Highlights disease. That is why we are excited about two recent uniformly shown in the blood of patients across 5-7 research projects that received a wide range of mitochondrial partial funding from the UMDF disorders,” he added. The team Adult Corner Research Grant Program. saw that levels of glutathione, the 9 In 2004, Gregory Enns, MD, body’s primary antioxidant, were ChB, and his team from Stanford significantly reduced in white blood Advocacy University School of Medicine cells from the 20 mitochondrial 10 and Lucile Packard Children’s disease patients in the study. Hospital were the recipients of a A second finding gave the Announcements grant for a project that devised a researchers information on potential 12 much needed way to monitor and treatments.
    [Show full text]
  • Diagnosis of Mitochondrial Diseases: Clinical and Histological Study of Sixty Patients with Ragged Red Fibers
    Original Article Diagnosis of mitochondrial diseases: Clinical and histological study of sixty patients with ragged red fibers Sundaram Challa, Meena A. Kanikannan*, Murthy M. K. Jagarlapudi**, Venkateswar R. Bhoompally***, Mohandas Surath*** Departmetns of Pathology and *Neurology, Nizam’s Institute of Medical Sciences, Hyderabad. **Institute of Neurological Sciences, Care Hospital, ***L.V. Prasad Eye Institute, Hyderabad, India. Background: Mitochondrial diseases are caused by muta- group of patients. tions in mitochondrial or nuclear genes, or both and most Key Words: Mitochondrial disease, Ragged-red fiber, Pro- patients do not present with easily recognizable disorders. gressive external ophthalmoplegia, Kearns-Sayre syndrome, The characteristic morphologic change in muscle biopsy, Myoclonus epilepsy with ragged-red fibers, Heart block. ragged-red fibers (RRFs) provides an important clue to the diagnosis. Materials and Methods: Demographic data, pre- senting symptoms, neurological features, and investigative findings in 60 patients with ragged-red fibers (RRFs) on muscle biopsy, seen between January 1990 and December Introduction 2002, were analyzed. The authors applied the modified res- piratory chain (RC) diagnostic criteria retrospectively to de- Mitochondrial diseases with ragged-red muscle fibers (RRF) termine the number of cases fulfilling the diagnostic criteria as well as some without RRF, are caused by mutations in mi- of mitochondrial disease. Results: The most common clini- tochondrial or nuclear genes, or both, which are normally in- cal syndrome associated with RRFs on muscle biopsy was volved in the formation and maintenance of a functionally in- progressive external ophthalmoplegia (PEO) with or with- tact oxidative phosphorylation system in the mitochondrial out other signs, in 38 (63%) patients. Twenty-six patients inner membrane.1 These disorders present, with bewildering (43%) had only external ophthalmoplegia, 5 (8%) patients array of clinical presentations and are usually dominated by presented with encephalomyopathy.
    [Show full text]